OncoCyte Corp logo

OncoCyte Corp

$ 0.71 -0.0235 (-3.2%) 04:00 PM EST
P/E:
At Loss
P/B:
1.02
Market Cap:
$ 84.19M
Enterprise V:
$ 50.96M
Volume:
549.88K
Avg Vol (2M):
354.26K
Also Trade In:
Volume:
549.88K
Market Cap $:
84.19M
PE Ratio:
At Loss
Avg Vol (2-Month):
354.26K
Enterprise Value $:
50.96M
PB Ratio:
1.02
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Name Current Vs Industry Vs History
Cash-To-Debt 9.99
Equity-to-Asset 0.52
Debt-to-Equity 0.05
Debt-to-EBITDA -0.07
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.08
Distress
Grey
Safe
Beneish M-Score -0.78
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 15.24
9-Day RSI 24.52
14-Day RSI 32.03
6-1 Month Momentum % -50.3
12-1 Month Momentum % -77.77

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.49
Quick Ratio 3.49
Cash Ratio 3.21
Days Inventory 13.2
Days Sales Outstanding 67.15
Days Payable 84.93

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -31.4
Name Current Vs Industry Vs History
Gross Margin % -4.27
Operating Margin % -650.48
Net Margin % -846.68
ROE % -82.89
ROA % -41.5
ROIC % -40.6
ROC (Joel Greenblatt) % -743.79
ROCE % -45.53

Financials (Next Earnings Date:2022-11-09 Est.)

OCX's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:OCX

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 8.064
EPS (TTM) ($) -0.72
Beta 0.56
Volatility % 32.97
14-Day RSI 32.03
14-Day ATR ($) 0.063146
20-Day SMA ($) 0.818965
12-1 Month Momentum % -77.77
52-Week Range ($) 0.68 - 3.73
Shares Outstanding (Mil) 118.61

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

OncoCyte Corp Filings

Document Form Filing Date
No Filing Data

OncoCyte Corp Analysis

Share your research

Headlines

See More
No news.